Literature DB >> 17094961

Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of tropisetron: role of alpha7 nicotinic receptors.

Kenji Hashimoto1, Yuko Fujita, Tamaki Ishima, Hiroko Hagiwara, Masaomi Iyo.   

Abstract

We examined the effects of tropisetron, a 5-hydroxytryptamine (5-HT(3)) receptor antagonist and alpha7 nicotinic receptor agonist, on cognitive deficits in mice after repeated administration of the NMDA receptor antagonist phencyclidine (PCP). PCP (10 mg/kg/day for 10 days)-induced cognitive deficits were significantly improved by subsequent subchronic (2 weeks) administration of tropisetron, but not ondansetron. Effects of tropisetron were significantly antagonized by co-administration of the alpha7 nicotinic receptor antagonist methyllycaconitine, suggesting the role of alpha7 nicotinic receptors in the active mechanisms of tropisetron. These findings suggest that tropisetron could be a potential therapeutic drug for cognitive deficits in schizophrenic patients.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17094961     DOI: 10.1016/j.ejphar.2006.09.055

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  21 in total

1.  Tropisetron enhances recognition memory in rats chronically treated with risperidone or quetiapine.

Authors:  Indrani Poddar; Patrick M Callahan; Caterina M Hernandez; Xiangkun Yang; Michael G Bartlett; Alvin V Terry
Journal:  Biochem Pharmacol       Date:  2017-11-24       Impact factor: 5.858

2.  Effects of the nicotinic α7 receptor partial agonist GTS-21 on NMDA-glutamatergic receptor related deficits in sensorimotor gating and recognition memory in rats.

Authors:  Patrick M Callahan; Alvin V Terry; Ashok Tehim
Journal:  Psychopharmacology (Berl)       Date:  2014-03-05       Impact factor: 4.530

Review 3.  Evaluating the role of the alpha-7 nicotinic acetylcholine receptor in the pathophysiology and treatment of schizophrenia.

Authors:  Jared W Young; Mark A Geyer
Journal:  Biochem Pharmacol       Date:  2013-07-12       Impact factor: 5.858

Review 4.  Mouse pharmacological models of cognitive disruption relevant to schizophrenia.

Authors:  Jared W Young; Susan B Powell; Mark A Geyer
Journal:  Neuropharmacology       Date:  2011-06-29       Impact factor: 5.250

5.  A randomised, double-blind, placebo-controlled trial of tropisetron in patients with schizophrenia.

Authors:  Akihiro Shiina; Yukihiko Shirayama; Tomihisa Niitsu; Tasuku Hashimoto; Taisuke Yoshida; Tadashi Hasegawa; Tadashi Haraguchi; Nobuhisa Kanahara; Tetsuya Shiraishi; Mihisa Fujisaki; Goro Fukami; Michiko Nakazato; Masaomi Iyo; Kenji Hashimoto
Journal:  Ann Gen Psychiatry       Date:  2010-06-24       Impact factor: 3.455

6.  Effects of nicotine on sensorimotor gating impairment induced by long-term treatment with neurotoxic NMDA antagonism.

Authors:  Bruce A Rasmussen; David C Perry; Jahn O'Neil; Kebreten F Manaye; Yousef Tizabi
Journal:  Neurotox Res       Date:  2008 May-Jun       Impact factor: 3.911

Review 7.  α7 nicotinic acetylcholine receptors as therapeutic targets in schizophrenia: Update on animal and clinical studies and strategies for the future.

Authors:  Alvin V Terry; Patrick M Callahan
Journal:  Neuropharmacology       Date:  2020-03-15       Impact factor: 5.250

8.  Effects of the antioxidant sulforaphane on hyperlocomotion and prepulse inhibition deficits in mice after phencyclidine administration.

Authors:  Yumi Shirai; Yuko Fujita; Kenji Hashimoto
Journal:  Clin Psychopharmacol Neurosci       Date:  2012-08-31       Impact factor: 2.582

9.  Occupancy of α7 Nicotinic Acetylcholine Receptors in the Brain by Tropisetron: A Positron Emission Tomography Study Using [(11)C]CHIBA-1001 in Healthy Human Subjects.

Authors:  Masatomo Ishikawa; Muneyuki Sakata; Jun Toyohara; Keiichi Oda; Kenji Ishii; Jin Wu; Taisuke Yoshida; Masaomi Iyo; Kiichi Ishiwata; Kenji Hashimoto
Journal:  Clin Psychopharmacol Neurosci       Date:  2011-12-31       Impact factor: 2.582

10.  Tropisetron But Not Granisetron Ameliorates Spatial Memory Impairment Induced by Chronic Cerebral Hypoperfusion.

Authors:  Ashkan Divanbeigi; Mohammad Nasehi; Salar Vaseghi; Sepideh Amiri; Mohammad-Reza Zarrindast
Journal:  Neurochem Res       Date:  2020-08-14       Impact factor: 3.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.